Editas Medicine to Participate in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

Chardan Virtual 4th Annual Genetic Medicines ConferenceFireside ChatDate: Monday, October 5, 2020Time: 10:30 a.m. ET

The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor ContactMark Mullikin(617) 401-9083[email protected]

Media ContactCristi Barnett(617) 401-0113[email protected]

You May Also Be Interested In

• HII’s Newport News Shipbuilding Completes Successful Acceptance Sea Trials of John F. Kennedy (CVN 79)
• The King Center and Divine Nine Launch Historic Fundraising Campaign to Preserve Critical History and Amplify Nonviolence365® Ahead of King100
• Crypto News Today: Bitcoin ETFs Lose $192M in 2 Days as AlphaPepe Buyers Hunt the Next PEPE Before the Chart